279 The phase 3 HELIOS-B trial (NCT04153149), a multicenter, double-blind, randomized controlled trial, recently reported that vutrisiran reduced the primary endpoint, a composite of all-cause mortality and recurrent cardiovascular events, by 28% in the overall population and by 33% in the monotherapy subgroup
Gut microbiotabile acidintestinal farnesoid X receptor signaling axis orchestrates cadmium-induced liver injury
Marginally, via barrier support) [14]
Pierotti MA, Berrino F, Gariboldi M, Melani C, Mogavero A, Negri T, Pasanisi P, Pilotti S
doi: 10.1007/s13300-020-00981-0 70 RosenstockJWyshamCFrasJPKanekoSLeeCJFernndez LandLet al
Collagen: Improves skin elasticity, moisture, and firmness